23,114 Shares in Nektar Therapeutics $NKTR Bought by GSA Capital Partners LLP

GSA Capital Partners LLP purchased a new position in Nektar Therapeutics (NASDAQ:NKTR) during the 4th quarter, Holdings Channel.com reports. The firm purchased 23,114 shares of the biopharmaceutical company’s stock, valued at approximately $977,000.

Several other large investors also recently bought and sold shares of NKTR. AQR Capital Management LLC increased its position in Nektar Therapeutics by 336.9% in the first quarter. AQR Capital Management LLC now owns 3,640,851 shares of the biopharmaceutical company’s stock worth $2,463,000 after purchasing an additional 2,807,595 shares during the last quarter. Farallon Capital Management LLC bought a new stake in Nektar Therapeutics in the third quarter worth $45,008,000. Two Sigma Investments LP increased its position in Nektar Therapeutics by 446.9% in the third quarter. Two Sigma Investments LP now owns 434,237 shares of the biopharmaceutical company’s stock worth $24,708,000 after purchasing an additional 354,842 shares during the last quarter. Emerald Advisers LLC bought a new stake in Nektar Therapeutics in the third quarter worth $18,393,000. Finally, Jefferies Financial Group Inc. bought a new stake in Nektar Therapeutics in the third quarter worth $17,252,000. Institutional investors own 75.88% of the company’s stock.

Nektar Therapeutics Stock Down 1.3%

NASDAQ NKTR opened at $68.58 on Friday. The company has a fifty day moving average of $78.11 and a two-hundred day moving average of $61.78. The firm has a market capitalization of $2.32 billion, a price-to-earnings ratio of -8.14 and a beta of 1.24. Nektar Therapeutics has a 52 week low of $7.99 and a 52 week high of $109.00.

Nektar Therapeutics (NASDAQ:NKTR) last posted its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported ($1.82) EPS for the quarter, missing the consensus estimate of ($1.58) by ($0.24). The firm had revenue of $10.86 million for the quarter, compared to analysts’ expectations of $10.69 million. Nektar Therapeutics had a negative return on equity of 85.40% and a negative net margin of 284.18%. Equities research analysts anticipate that Nektar Therapeutics will post -9.65 EPS for the current year.

Analyst Upgrades and Downgrades

NKTR has been the topic of several research reports. Jefferies Financial Group restated a “buy” rating on shares of Nektar Therapeutics in a research report on Wednesday, April 22nd. Oppenheimer restated an “outperform” rating and issued a $140.00 price target on shares of Nektar Therapeutics in a research report on Friday, March 13th. Wall Street Zen upgraded shares of Nektar Therapeutics from a “sell” rating to a “hold” rating in a research report on Sunday, May 17th. William Blair upgraded shares of Nektar Therapeutics from a “market perform” rating to an “outperform” rating in a research report on Tuesday, February 10th. Finally, BTIG Research boosted their price target on shares of Nektar Therapeutics from $151.00 to $178.00 and gave the stock a “buy” rating in a research report on Monday, April 20th. Nine research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $149.63.

Insider Buying and Selling

In other Nektar Therapeutics news, CEO Howard W. Robin sold 444 shares of Nektar Therapeutics stock in a transaction on Tuesday, May 19th. The shares were sold at an average price of $65.51, for a total transaction of $29,086.44. Following the completion of the transaction, the chief executive officer directly owned 75,045 shares of the company’s stock, valued at $4,916,197.95. The trade was a 0.59% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 2.50% of the stock is owned by insiders.

Nektar Therapeutics Profile

Nektar Therapeutics (NASDAQ:NKTR) is a biopharmaceutical company dedicated to discovering and developing novel drug candidates through its proprietary chemistry and immunology platforms. The company focuses on polymer conjugate technology, which enables the creation of longer-acting versions of existing drugs, and on T-cell modulatory therapies aimed at harnessing the body’s immune system to treat cancer and other serious diseases.

Nektar’s product portfolio and pipeline include a range of clinical-stage and partnered programs.